MTARC1 and steatosis: In several mouse models of MASH and liver fibrosis, we found that loss of mARC1 by genetic deletion or siRNA-mediated hepatocyte-specific knockdown resulted in improved liver endpoints including decreased steatosis, fibrosis, and circulating ALT and total cholesterol levels.